Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics
  >  
JAK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

JAK

Chemical Structure Cat. No. Product Name CAS No.
WHI-P 97 Chemical Structure
BCP29062 WHI-P 97 211555-05-4
WHI-P97 is a rationally designed potent inhibitor of JAK-3.
BMS-986165 Chemical Structure
BCP30443 BMS-986165 1609392-27-9
BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).
Abrocitinib Chemical Structure
BCP30441 Abrocitinib 1622902-68-4
Abrocitinib, also known as PF-04965842, is an oral Janus Kinase 1 inhibitor being investigated for treatment of plaque psoriasis.
JAK3-IN-6 Chemical Structure
BCP30249 JAK3-IN-6 1443235-95-7
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM.
Baricitinib trifluoroacetate Chemical Structure
BCP16048 Baricitinib trifluoroacetate 1187594-10-0
Baricitinib, also known as INCB 028050 or LY 3009104, is an orally administered selective JAK1 andk JAK 2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK 2( 5.7 nM).
Ruxolitinib maleic acid salt Chemical Structure
BCP30121 Ruxolitinib maleic acid salt 1092939-15-5
Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.
Ruxolitinib sulfate Chemical Structure
BCP27733 Ruxolitinib sulfate 1092939-16-6
Ruxolitinib sulfate is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
CEP33779 Chemical Structure
BCP27756 CEP33779 1257704-57-6
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
TG46 Chemical Structure
BCP28052 TG46 936091-15-5
TG-46 is an inhibitor of JAK2, FLT3, RET, JAK3.
SB1317 Chemical Structure
BCP27919 SB1317 1204918-72-8
SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.
123下一页末页共 68 条记录 1 / 7 页 
0086-13720134139